From early development to market access and beyond, we deliver integrated advice and evidence driven solutions that help innovative medicines and vaccines achieve sustainable access and better health outcomes.
Learn More About Us Contact UsA unique fusion of public health leadership and market access expertise.
Over 22 years of experience in infectious diseases, vaccines, market access and health policy.
✓ Former Director of Market Access & Policy Affairs, Moderna UK & Ireland
✓ Previous Senior Leadership roles at SPMSD, Sanofi and Biogen
✓ Former Senior Expert Adviser, UK Government
✓ Author of 180+ peer reviewed papers
✓ Honorary Assistant Professor at University of Nottingham
Internationally recognised leader in public health, respiratory viruses and pandemic response.
✓ Former Deputy Chief Medical Officer for England (2017-2022)
✓ Knighted in 2022 for services to public health
✓ Extensive academic and government experience
✓ Trusted adviser on vaccines, pandemic preparedness and health strategy
CVT Market Access Solutions Ltd creates a fusion of Stuart Carroll’s two decades of experience across vaccines, infectious diseases, market access and public health policy, with Jonathan Van-Tam’s lifetime of medical and public health policy expertise. This creates a unique offering for clients, especially pharmaceutical companies seeking to navigate complex healthcare ecosystems and policy landscapes to secure sustainable access for innovative medicines and vaccines. The firm combines expertise in market access strategy, health economics and outcomes research (HEOR), pricing and reimbursement, medical affairs, and government policy with deep experience in public health and health technology assessment.
CVT advisors work at the intersection of science, medicine, policy and healthcare systems, to provide strategic support and advice across the full product lifecycle, from early evidence generation and access strategy through to policy engagement, reimbursement negotiations and stakeholder communications.
Market Access and
Strategy
HEOR & Evidence Generation
Pricing &
Reimbursement
Medical Affairs &
Policy
Government &
Health Policy
Medical Affairs & Scientific Strategy
A one-day intensive workshop for pharmaceutical and vaccine industry professionals seeking to better understand the UK vaccination policy ecosystem.
Led by: Professor Sir Jonathan Van-Tam and Stuart Carroll
This intensive one-day expert workshop will help delegates better understand how UK vaccination policy is developed, regulated, and implemented in the United Kingdom. The focus will be on the Joint Committee on Vaccination and Immunisation (JCVI) around which the entire UK vaccines ecosystem pivots. The JCVI is widely regarded as one of the best, if not the best, national immunisation technical advisory groups in the world. It has been a safe and reliable custodian of the UK vaccine programme for as long as it has existed, with very few missteps, by way of under- or over-reacting.
Yet for those less familiar, the JCVI can be hard to understand in terms of what it is, and why it is the way it is (its history and legacy), where it sits and how it operates in the wider vaccine policy-setting framework, and what the limits of its jurisdiction and power actually are. It is also a committee arguably not renowned for ease of access or the most open style of communication. In short, it has a distinctive ‘persona’ and place in the UK vaccines ecosystem.
This workshop will examine all the above in a concentrated one-day format: the full pathway from vaccine development and regulatory approval through to policy adoption and population rollout, centred on the JCVI itself. Participants will engage with the scientific, economic, regulatory, and political dimensions of vaccine decision-making, drawing on real-world principle-based* case studies from COVID-19 and business-as-usual operating. The course is designed to be useful to pharmaceutical and vaccine industry professionals (market access, commercial, marketing, HEOR and medical affairs), especially those at earlier career stages or new entrants to the vaccines space, for whom it would be an advantage to upskill as fast as possible.
The workshop will be based on a small number of participants**, in a safe space to explore a detailed understanding of this environment, and taught by two experienced professionals who together have seen and experienced almost all aspects of the UK vaccine policy space.
*no confidential facts or materials will be used or shared
**the course size is capped at 20 persons, and will be offered on a first come, first served basis. Places are limited. Early registration is therefore recommended.
Date:
Tuesday 8th September 2026
Location:
Very Central London (exact location will be confirmed to registering delegates)
Timings:
0930 to 1630 (TBC)
Format:
Small-group, in-person expert workshop
Capacity:
Capped at 20 participants
Includes:
Tea, coffee and light lunch
Cost:
£675 + VAT
✓ JCVI history, legacy and ‘persona’
✓ JCVI roles and roles that are not JCVI’s
✓ Vaccine journeys from UK licensure to NHS implementation
✓ Criteria for JCVI evaluation and how this works in practice
✓ Admissible and inadmissible evidence
✓ Handling of HEOR data and economic modelling
✓ The role of UK Health Security Agency as committee secretariat
✓ Approach routes, industry interactions and touchpoints
✓ Interpreting JCVI minutes
✓ Other stakeholders in the vaccine policy space
✓ Principles of interactions between JCVI, MHRA, UKHSA, DHSC, and ministers
✓ Opportunities for direct Q&A with two leading experts
✓ Future implications of Most Favoured Nation and Trump Executive Order
Stuart Carroll is a senior health economist and epidemiologist with over 22 years of experience, specialising in infectious diseases and vaccines, market access, health technology appraisal, public health, and public affairs and government policy. He recently worked for Moderna as Director of Market Access and Policy Affairs, Moderna UK and Ireland for four years where he also helped negotiate the UK Government's Strategic Partnership for pandemic preparedness. He previously worked for Her Majesty’s Government as a Senior Expert Policy and Strategy Adviser for the Prime Minister’s UK Vaccines Taskforce and the Antiviral and Therapeutics Taskforce where he was responsible for coordinating strategy on deployment and implementation imperatives as well as providing expert advice on supply and procurement to the Joint Committee on Vaccination and Immunisation (JCVI) and leading on the Northern Ireland Protocol and assisting with drafting the Windsor Framework. Stuart also specialises in health policy and market access matters relating to rare diseases, neurology and mental health, and has published over 180 peer review academic and scientific papers.
Previously, Stuart has worked in consultancy, acted as a Health Policy Adviser to the Conservative Party and undertaken multiple industry roles including as Head of Market Access and Public Affairs for Sanofi Pasteur UK and Ireland and previously Head of Market Access for Biogen and Head of Health Economics and Epidemiology for Sanofi Pasteur MSD. He has also served as a full voting member of the New Drugs Committee to the Scottish Medicines Consortium and a member of the National Institute for Health and Care Excellence Appeals Panel. He is a Fellow of The Royal Society for Public Health and Royal Society of Arts, a Senior Fellow at Policy Exchange and the Office of Health Economics. Stuart has previously acted as visiting lecturer to Imperial Business School. He is currently the Co-Chair of the Association of the British Pharmaceutical Industry Vaccines Group and in 2019 General Election acted as the former Prime Minister, Theresa May’s Chief of Staff.
Stuart holds a BA (Hons) in Politics and Economics (1st Class) from the University of Northumbria at Newcastle, an MSc in Health Economics (Distinction) from the University of York, and an MBA (Distinction) from Imperial Business School. He is currently completing a PhD in public health and public policy at the University of Nottingham.
Stuart also served as an elected councillor where he represented Boyn Hill in the Royal Borough of Windsor, Ascot and Maidenhead between 2015-2023 and also served as the Deputy Chair of Cabinet, the Cabinet Member for Adult Social Care, Health, Mental Health and Children’s Services and the Chairman of the Health and Wellbeing Board. He has extensive experience across public and government affairs including communications strategy.
Stuart was appointed an Honorary Assistant Professor at the University of Nottingham in April 2026 in the School of Medicine where his research and teaching focuses on public health, vaccination, pandemic preparedness and health economic applications.
Professor Sir Jonathan Van-Tam, MBE, is an internationally recognised physician, public health expert and authority on respiratory viruses and pandemics. He served as England’s Deputy Chief Medical Officer between 2017 and 2022 and played a leading role in the UK’s response to the COVID-19 pandemic. His career has spanned academia (research, teaching and Pro-Vice Chancellor), central government (Department of Health and Social Care), government agencies (Public Health Laboratory Service, Health Protection Agency, Public Health England), international public health (WHO and ECDC advisory positions) and the pharmaceutical and vaccine industries, including serving as Head of Medical Affairs at Roche UK, and UK Medical Director of Sanofi Pasteur MSD. In all these roles, his trademark modus operandi has been one of an able communicator and translator at disciplinary interfaces: science, medicine, public health policy, marketing, market access, medical affairs and clinical development. Widely recognised for his strategic vision, and clear and effective public communication of complex scientific issues, he was knighted in 2022 for services to public health and awarded the Royal Society’s Attenborough Award for outstanding public engagement in science. He is a Fellow of the Academy of Medical Sciences, the Royal College of Pathologists and an Honorary Fellow of the Faculty of Public Health, the Faculty of Pharmaceutical Medicine and the Royal Society of Public Health. He now advises a range of scientific and corporate organisations on vaccines, pandemic preparedness and public health strategy.